News

According to the US biopharma company, lebrikizumab is a monoclonal antibody that can bind with very high affinity with the Interleukin 13 (IL-13) cykotine. Through this mechanism, the

Vedanta also announced the formation of its Immuno-Oncology Scientific Advisory Board (SAB), which is comprised of experts in immunology, immuno-oncology and the microbiome, to support the planned clinical

Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors. By recapitulating

Under the deal, Amneal will acquire a 65.1% stake in AvKARE and its related affiliate conducting business as R&S Northeast. AvKARE is a private label provider of generic

Headquartered in California, Synthorx is focused on developing therapies for cancer and autoimmune disorders. Sanofi is offering to buy the biotechnology company at $68 per share. THOR-707, the

These analyses are from a readout of a 15-year post-marketing study that add to and complement the rigor of the Kymriah pivotal trials with evidence of the Kymriah

Aiming to attract global advanced biotechnology companies and research institutions, the City authorities will expand the industrial complex by adding the 11th Songdo industrial block with space of

ArQule is involved in the research and development of targeted therapeutics for the treatment of cancers and certain rare diseases. The company’s clinical-stage pipeline consists of four drug

According to XBiotech, bermekimab has been designed to neutralise interleukin-1 alpha (IL-1⍺), which is known for promoting disease-causing inflammation in a wide variety of medical conditions. As per